CD274 and esophageal squamous cell carcinoma: In KEYNOTE-181, pembrolizumab prolonged OS compared with chemotherapy in patients with ESCC PD-L1 CPS ≥ 10 (HR, 0.64; 95% CI 0.46–0.90) [6, 18].